

REMARKS

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a text copy of the Substitute Sequence Listing. The text copy of the Sequence Listing is identical to the paper copy, except that it lacks formatting.


The specification and claims are amended to identify each amino acid sequence with a corresponding SEQ ID NO. The Sequence Listing is amended to correct formatting errors and to reference the present application by filing date and serial number. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

MAR 27 2007

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977
P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/psq/las
3691-0125PUS1

Attachments